EP300 deficiency leads to chronic replication stress mediated by defective replication fork protection.

TitleEP300 deficiency leads to chronic replication stress mediated by defective replication fork protection.
Publication TypeJournal Article
Year of Publication2025
AuthorsBarreto-Galvez A, Niljikar M, Gagliardi JElizabeth, Guzman CPlasencia, Zhang R, Kumar V, Juwarwala A, Pradeep A, Saxena A, Montagna C, Mittal P, Gerhardt J, Xia B, Cao J, Kataoka K, Durbin ADavid, Qi J, B Ye H, Madireddy A
JournalNat Commun
Volume17
Issue1
Pagination475
Date Published2025 Dec 07
ISSN2041-1723
KeywordsBRCA2 Protein, Cell Line, Tumor, DNA Replication, E1A-Associated p300 Protein, Genomic Instability, Humans, Mutation, Replication Origin
Abstract

Mutations in the global transcriptional activator EP300/KAT3B are being reported in aggressive malignancies. However, the mechanistic contribution of EP300 dysregulation to cancer is currently unknown. While EP300 has been implicated in regulating cell cycle and DNA replication, the role of EP300 in maintaining replication fork integrity has not been studied. Here, using EP300-mutated adult T-cell leukemia/lymphoma cells and an EP300-selective degrader, we reveal that EP300 loss leads to pronounced dysregulations in DNA replication dynamics and persistent genomic instability. Aberrant DNA replication in EP300-mutated cells is characterized by elevated replication origin firing due to replisome pausing. EP300 deficiency results in a prominent defect in fork protection resulting in the accumulation of single-stranded DNA gaps. Importantly, we find that the loss of EP300 results in decreased expression of BRCA2 protein leading to sensitivity to treatments that are cytotoxic to BRCA-deficient cancers. Overall, we demonstrate that EP300-mutated cells recapitulate features of BRCA-deficient cancers.

DOI10.1038/s41467-025-67171-z
Alternate JournalNat Commun
PubMed ID41354653
PubMed Central IDPMC12800293
Grant ListP01250957-9485 / / U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) /
R00 HL136870 / HL / NHLBI NIH HHS / United States
R01CA262227 / / U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) /
R01 CA266847 / CA / NCI NIH HHS / United States
R01 ES034733 / ES / NIEHS NIH HHS / United States
R01 CA138804 / CA / NCI NIH HHS / United States
R01CA266847 / / U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) /
P01 CA250957 / CA / NCI NIH HHS / United States
R35 GM152228 / GM / NIGMS NIH HHS / United States
R01CA138804 / / U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) /
R00HL136870 / / U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) /
K08CA245251 / / Center for Strategic Scientific Initiatives, National Cancer Institute (NCI Center for Strategic Scientific Initiatives) /
R01 CA262227 / CA / NCI NIH HHS / United States
K08 CA245251 / CA / NCI NIH HHS / United States
R01ES034733 / / U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences (NIEHS) /
R01 CA275187 / CA / NCI NIH HHS / United States
R37 CA286444 / CA / NCI NIH HHS / United States